Clinical and Collaborative Care Strategies for the Successful Management of Hemophilia

• Release Date: April 19, 2017
• Expiration Date: October 31, 2018
• Estimated Time to Complete Activity: 1.0 hour
• Compatible with all modern browsers and mobile devices

DISTINGUISHED FACULTY

Amber Federizo, APRN, FNP-BC Nurse Practitioner Hemophilia Treatment Center of Nevada Click here for biography Surabhi Palkimas, PharmD Pharmacy Clinical Coordinator, Hematology University of Virginia Health System Click here for biography

TARGET AUDIENCE

• Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
• Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for hemophilia patients including: physicians, pharmacists, and nurses

Statement of Need/Program Overview
Due to the advent of new and more costly treatment modalities, the management of pediatric and adult hemophilia patients has become more complex for health care providers. In the absence of a coordinated educational effort, the full benefits of care coordination and the comprehensive care model have not yet been achieved. Appropriate management is vital to minimizing and preventing long-term issues that can contribute to higher costs. This activity will provide clinical updates and recommended guidelines and will showcase an interactive case study discussion between the expert faculty panel, which includes an HTC provider and a hemophilia-focused health-system pharmacist.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

• Describe current and evolving strategies for health-system pharmacists to facilitate high quality care for patients with hemophilia
• Cite the most recent clinical recommendations for the treatment of patients with hemophilia, including investigational agents and the role of novel agents
• Explain hemophilia-related complications associated with emergency department visits and its significant clinical and economic consequences
• Identify processes for health-system pharmacists to improve communications and collaborations with hemophilia treatment centers (HTCs)

ACCREDITATION

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources, Inc. (MER), National Hemophilia Foundation, and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

	Accreditation Statement  Medical Education Resources, Inc. (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
MER designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - 0816-9999-17-088-H01-P.

Nursing Continuing Education
Accreditation Statement 
Medical Education Resources, Inc. (MER) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. MER is accredited as a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Credit Designation
This CE activity provides 1.0 contact hours of continuing nursing education.

DISCLOSURE OF CONFLICTS OF INTEREST
It is the policy of Medical Education Resources, Inc. (MER) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Inc., Impact Education, LLC, the National Hemophilia Foundation, Alnylam Pharmaceuticals, Novo Nordisk, Inc. and/or Shire. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Medical Education Resources, Inc., Impact Education, LLC, the National Hemophilia Foundation, Alnylam Pharmaceuticals, Novo Nordisk, Inc. and/or Shire. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period April 19, 2017 through October 31, 2018, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 70% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon completion of the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.